留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展

李翰 贾亚男 贺强 李先亮

李翰, 贾亚男, 贺强, 等. 危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展[J]. 器官移植, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004
引用本文: 李翰, 贾亚男, 贺强, 等. 危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展[J]. 器官移植, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004
Li Han, Jia Yanan, He Qiang, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004
Citation: Li Han, Jia Yanan, He Qiang, et al. Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 344-349. doi: 10.3969/j.issn.1674-7445.2020.03.004

危重症肝病肝移植术后免疫抑制剂管理和感染的防治进展

doi: 10.3969/j.issn.1674-7445.2020.03.004
基金项目: 

国家自然科学基金 81571554

详细信息
    作者简介:

    李翰:李瀚,男,1987年生,硕士,住院医师,研究方向为器官移植诱导免疫耐受,Email: lihanw11@163.com

    李先亮,副主任医师、副教授、硕士研究生导师。兼任中华医学会器官移植研究学组委员、中华医学会实验外科学组委员、中国医师协会器官移植免疫学组委员、中国健康促进协会精准医疗与肿瘤康复专业委员会常务理事、中国医疗保健国际促进会肝脏移植分会代谢管理学组副组长、中国医疗保健国际促进会肝脏移植分会委员、海峡两岸医药卫生交流协会肝胆胰外科专业委员会委员、中国医药生物技术协会生物技术诊断分会常委等。兼任世界器官移植协会会员、欧洲器官移植协会会员。2004年师从范上达院士获香港大学博士,2006年获得国际移植专业协会大奖,2008年世界器官移植大会受邀报告,并担任分会场的执行主席,2009年获欧洲器官移植协会奖励,2010年从法国被人才引进首都医科大学附属北京朝阳医院,2014年入选科学中国人杂志医药卫生领域年度人物,2017年获得''人民好医生''称号,2018年获得北京经济技术开发区''亦麒麟''人才称号

    通讯作者:

    李先亮,Email:lixianliangbjcy@126.com

  • 中图分类号: R617, R575.3

Progress of immunosuppressant management, infection prevention and treatment after liver transplantation in severe liver disease

More Information
  • 摘要: 肝移植是危重症肝病的有效治疗手段,但是危重症肝病患者病理生理改变复杂,肝移植围手术期管理难度增大。因此,加强危重症肝病受者肝移植术后的管理具有重要意义。本文就危重症肝病的病理生理特点、肝移植术后免疫抑制药物选择、危重症肝病肝移植术后感染预防及治疗等方面做一综述。

     

  • [1] RANA A, ACKAH RL, WEBB GJ, et al. No gains in long-term survival after liver transplantation over the past three decades[J]. Ann Surg, 2019, 269(1):20-27. DOI: 10.1097/SLA.0000000000002650.
    [2] OLIVO R, GUARRERA JV, PYRSOPOULOS NT. Liver transplantation for acute liver failure[J]. Clin Liver Dis, 2018, 22(2):409-417. DOI: 10.1016/j.cld.2018.01.014.
    [3] GERMANI G, THEOCHARIDOU E, ADAM R, et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database[J]. J Hepatol, 2012, 57(2):288-296. DOI: 10.1016/j.jhep. 2012.03.017.
    [4] BERNAL W, JALAN R, QUAGLIA A, et al. Acute-onchronic liver failure[J]. Lancet, 2015, 386(10003):1576- 1587. DOI: 10.1016/S0140-6736(15)00309-8.
    [5] BERNAL W, WENDON J. Acute liver failure[J]. N Engl J Med, 2013, 369(26):2525-2534. DOI: 10.1056/NEJMra1208937.
    [6] European Association for the Study of the Liver, Clinical Practice Guidelines Panel, WENDON J, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66(5):1047- 1081. DOI: 10.1016/j.jhep.2016.12.003.
    [7] STRAVITZ RT, LEE WM. Acute liver failure[J]. Lancet, 2019, 394(10201):869-881. DOI: 10.1016/S0140-6736(19) 31894-X.
    [8] UMGELTER A, LANGE K, KORNBERG A, et al. Orthotopic liver transplantation in critically ill cirrhotic patients with multi-organ failure: a single-center experience[J]. Transplant Proc, 2011, 43(10):3762-3768. DOI: 10.1016/j.transproceed.2011.08.110.
    [9] HWANG W, LEE J. Pathophysiologic implications of cytokines secretion during liver transplantation surgery[J]. Int J Med Sci, 2018, 15(14):1737-1745. DOI: 10.7150/ijms.28382.
    [10] MARUDANAYAGAM R, SHANMUGAM V, SANDHU B, et al. Liver retransplantation in adults: a single-centre, 25-year experience[J]. HPB (Oxford), 2010, 12(3):217- 224. DOI: 10.1111/j.1477-2574.2010.00162.x.
    [11] UMBRO I, TINTI F, SCALERA I, et al. Acute kidney injury and post-reperfusion syndrome in liver transplantation[J]. World J Gastroenterol, 2016, 22(42): 9314-9323. doi: 10.3748/wjg.v22.i42.9314
    [12] SOOD S, TESTRO AG. Immune monitoring post liver transplant[J]. World J Transplant, 2014, 4(1):30-39. DOI: 10.5500/wjt.v4.i1.30.
    [13] LUO Y, JI WB, DUAN WD, et al. Delayed introduction of immunosuppressive regimens in critically ill patients after liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(5):487-492. DOI: 10.1016/S1499- 3872(17)60050-X.
    [14] LING X, XIONG J, LIANG W, et al. Can immune cell function assay identify patients at risk of infection or rejection? a Meta-analysis[J]. Transplantation, 2012, 93(7):737-743. DOI: 10.1097/TP.0b013e3182466248.
    [15] CHARLTON M, LEVITSKY J, AQEL B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5):727-743. DOI: 10.1097/TP.0000000000002147.
    [16] NEUBERGER JM, MAMELOK RD, NEUHAUS P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study[J]. Am J Transplant, 2009, 9(2):327-336. DOI: 10.1111/j.1600-6143.2008.02493.x.
    [17] TRUNEČKA P, KLEMPNAUER J, BECHSTEIN WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study[J]. Am J Transplant, 2015, 15(7):1843-1854. DOI: 10.1111/ajt.13182.
    [18] LUÉ A, MARTINEZ E, NAVARRO M, et al. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation[J]. Transplantation, 2019, 103(8):e211-e215. DOI: 10.1097/TP.0000000000002750.
    [19] 刘焕业, 寇建涛, 马军, 等.肝移植治疗肝昏迷的围手术期管理经验探讨[J].器官移植, 2019, 10(3):323-327. DOI: 10.3969/j.issn.1674-7445.2019.03.017.

    LIU HY, KOU JT, MA J, et al. Experience in perioperative management of liver transplantation in hepatic coma patients[J]. Organ Transplant, 2019, 10(3):323-327. DOI: 10.3969/j.issn.1674-7445.2019.03.017.
    [20] ASRANI SK, WIESNER RH, TROTTER JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial[J]. Am J Transplant, 2014, 14(2):356-366. DOI: 10.1111/ajt.12543.
    [21] 张冬华, 陈榕, 王轩, 等.肝移植术后应用巴利昔单克隆抗体诱导的无糖皮质类固醇激素免疫抑制治疗方案的临床疗效[J].中华消化外科杂志, 2018, 17(10):997- 1001. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.006.

    ZHANG DH, CHEN R, WANG X, et al. Clinical efficacy of basiliximab-induced glucose-free corticosteroid immunosuppressive regimen after liver transplantation[J]. Chin J Digest Surg, 2018, 17(10):997- 1001. DOI: 10.3760/cma.j.issn.1673-9752.2018.10.006.
    [22] SEGEV DL, SOZIO SM, SHIN EJ, et al. Steroid avoidance in liver transplantation: Meta-analysis and Meta-regression of randomized trials[J]. Liver Transpl, 2008, 14(4):512-525. DOI: 10.1002/lt.21396.
    [23] FAIRFIELD C, PENNINGA L, POWELL J, et al. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients[J]. Cochrane Database Syst Rev, 2018, 4:CD007606. DOI: 10.1002/14651858.CD007606.pub4.
    [24] BERTACCO A, BARBIERI S, GUASTALLA G, et al. Risk factors for early mortality in liver transplant patients[J]. Transplant Proc, 2019, 51(1):179-183. DOI: 10.1016/j.transproceed.2018.06.025.
    [25] ABAD CL, LAHR BD, RAZONABLE RR. Epidemiology and risk factors for infection after living donor liver transplantation[J]. Liver Transpl, 2017, 23(4):465-477. DOI: 10.1002/lt.24739.
    [26] MOON DB, LEE SG. Liver transplantation[J]. Gut Liver, 2009, 3(3):145-165. DOI: 10.5009/gnl.2009.3.3.145.
    [27] 吴金道, 母小新, 韩国勇, 等.2012-2015年1380株肝移植术后感染病原菌的分布及耐药性分析[J].现代药物与临床, 2015, 30(12):1546-1549. DOI:10.7501/j.issn. 1674-5515.2015.12.027.

    WU JD, MU XX, HAN GY, et al. Analysis on distribution and drug resistance of 1380 strains of pathogens infected after liver transplantation from 2012 to 2015[J]. Mod Drug Clin, 2015, 30(12):1546-1549. DOI:10.7501/j.issn. 1674-5515.2015.12.027.
    [28] 李先亮, 吕少诚, 郎韧, 等.同种异体肝移植术后感染的常见病原菌分析[J].中华肝胆外科杂志, 2017, 23(3):205- 206. DOI:10.3760/cma.j.issn.1007-8118.2017.03.018.

    LI XL, LYU SC, LANG R, et al. Analysis of common pathogenic bacteria after liver allograft transplantation[J]. Chin J Hepatobil Surg, 2017, 23(3):205-206. DOI: 10.3760/cma.j.issn.1007-8118.2017.03.018.cma.j.issn.1007-8118.2017.03.018.
    [29] 张达利, 高银杰, 冯丹妮, 等.肝移植术后卡氏肺孢子菌肺炎1例报告[J].临床肝胆病杂志, 2019, 35(2):384- 385. DOI: 10.3969/j.issn.1001-5256.2019.02.030.

    ZHANG DL, GAO YJ, FENG DN, et al. A case of pneumocystis carini pneumonia after liver transplantation[J]. J Clin Hepatol, 2019, 35(2):384-385. DOI:10.3969/j.issn.1001-5256. 2019.02.030.
    [30] AYVAZOGLU SOY EH, AKDUR A, YILDIRIM S, et al. Early postoperative infections after liver transplant[J]. Exp Clin Transplant, 2018, 16 (Suppl 1):145-148. DOI: 10.6002/ect.TOND-TDTD2017.P36.
    [31] KIM SI. Bacterial infection after liver transplantation[J]. World J Gastroenterol, 2014, 20(20):6211-6220. DOI: 10.3748/wjg.v20.i20.6211.
    [32] SHI SH, KONG HS, JIA CK, et al. Coagulase-negative staphylococcus and enterococcus as predominant pathogens in liver transplant recipients with Grampositive coccal bacteremia[J]. Chin Med J (Engl), 2010, 123(15):1983-1988. https://www.cabdirect.org/cabdirect/abstract/20113029806
    [33] BODRO M, SABÉ N, TUBAU F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients[J]. Transplantation, 2013, 96(9):843-849. DOI: 10.1097/TP.0b013e3182a049fd.
    [34] CERVERA C, VAN DELDEN C, GAVALDÀ J, et al. Multidrug-resistant bacteria in solid organ transplant recipients[J]. Clin Microbiol Infect, 2014, 20(Suppl 7): 49-73. DOI: 10.1111/1469-0691.12687.
    [35] ZICKER M, COLOMBO AL, FERRAZ-NETO BH, et al. Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre[J]. Mem Inst Oswaldo Cruz, 2011, 106(3):339-345. doi: 10.1590/S0074-02762011000300014
    [36] SALIBA F, DELVART V, ICHAÏ P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era[J]. Clin Transplant, 2013, 27(4):E454-E461. DOI: 10.1111/ctr.12129.
    [37] BARCHIESI F, MAZZOCATO S, MAZZANTI S, et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases[J]. Liver Transpl, 2015, 21(2):204-212. DOI: 10.1002/lt.24032.
    [38] HOGEN R, DHANIREDDY KK. Invasive fungal infections following liver transplantation[J]. Curr Opin Organ Transplant, 2017, 22(4):356-363. DOI: 10.1097/MOT.0000000000000431.
    [39] 中华医学会器官移植学分会.器官移植受者侵袭性真菌病临床诊疗技术规范(2019版)[J].器官移植, 2019, 10 (3):227-236. DOI: 10.3969/j.issn.1674-7445.2019.03.002.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment for invasive fungal disease in organ transplant recipients (2019 edition)[J]. Organ Transplant, 2019, 10(3):227-236. DOI:10.3969/j.issn. 1674-7445.2019.03.002.
    [40] EKENBERG C, DA CUNHA-BANG C, LODDING IP, et al. Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation[J]. Transpl Infect Dis, 2020:e13252. DOI: 10.1111/tid.13252.
    [41] NAM H, NILLES KM, LEVITSKY J, et al. Donorderived viral infections in liver transplantation[J]. Transplantation, 2018, 102(11):1824-1836. DOI: 10.1097/TP.0000000000002326.
    [42] 中华医学会器官移植学分会.器官移植受者巨细胞病毒感染临床诊疗规范(2019版)[J].器官移植, 2019, 10(2): 142-148. DOI:10.3969/j.issn.1674-7445.2019.02.005.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for cytomegalovirus infection on recipients with organ transplantation in China (2019 edition)[J]. Organ Transplant, 2019, 10(2):142-148. DOI:10.3969/j.issn.1674-7445.2019.02.005.
    [43] 中华医学会器官移植学分会.器官移植受者EB病毒感染和移植后淋巴组织增生性疾病临床诊疗规范(2019版)[J].器官移植, 2019, 10(2):149-157.DOI: 10.3969/j.issn.1674-7445.2019.02.006.

    Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for EB virus infection and posttransplant lymphoproliferative disease on recipients with organ transplantation in China (2019 edition) [J]. Organ Transplant, 2019, 10(2):149-157. DOI: 10.3969/j.issn.1674-7445.2019.02.006.
    [44] ALLEN UD, PREIKSAITIS JK, AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4):107-120. DOI: 10.1111/ajt.12104.
    [45] MUMTAZ K, FAISAL N, MARQUEZ M, et al. Posttransplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a singlecentre experience with > 1000 liver transplantations[J]. Can J Gastroenterol Hepatol, 2015, 29(8):417-422. doi: 10.1155/2015/517359
    [46] ANGARITA SAK, RUSSELL TA, KALDAS FM. Pneumonia after liver transplantation[J]. Curr Opin Organ Transplant, 2017, 22(4):328-335. DOI: 10.1097/MOT.0000000000000427.
  • 加载中
计量
  • 文章访问数:  171
  • HTML全文浏览量:  68
  • PDF下载量:  42
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-02-07
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-05-15

目录

    /

    返回文章
    返回